Marker Therapeutics prioritizes MT-601 for CAR T-relapsed lymphoma, discontinues patient-specific AML program

Marker Therapeutics, Inc.

MT-601 for DLBCL patients who relapsed after CAR T: first APOLLO participant maintained complete response at 6 months.
Patient-specific AML program (ARTEMIS) discontinued due to manufacturing delays; shift to ready-to-use MT-401 from healthy donors.
Non-dilutive funding secured for off-the-shelf AML program; cash runway extended into Q4 2025.
Pancreatic cancer Phase 1 IND cleared but advancement pending additional non-dilutive funding.
MultiTAA T cell therapies shown safe in over 200 patients; no treatment-related adverse events in APOLLO or ARTEMIS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.